Common variations in platelet glycoproteins: pharmacogenomic implications

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Hematology

Background:

• Atherosclerosis involves complex genetic and environmental interactions, with platelets playing a key role.
• Antiplatelet agents are crucial for treatment, but individual responses vary significantly.
• Genetic factors are implicated in this variability, as platelet proteins are highly polymorphic.

Purpose of the Study:

• To discuss the current understanding of how genetic makeup influences antiplatelet therapy effectiveness and safety.
• To explore the role of common genetic variations (polymorphisms) in platelet function and drug response.
• To highlight specific polymorphisms in platelet receptors and their potential clinical implications.

Main Methods:

• Review of existing literature on genetic polymorphisms in platelet receptors.
• Analysis of studies investigating the association between genetic variations and antiplatelet drug response.
• Discussion of identified mutations in platelet receptors like GP IIb/IIIa, GPIa, GPVI, GPIb-IX, and P2Y(12).

Main Results:

• Up to 30% of natural variation in platelet reactivity is genetically determined.
• Specific polymorphisms, such as the (A2) allele, are linked to aspirin resistance and increased platelet responsiveness.
• Conflicting reports exist regarding the association of certain polymorphisms with coronary artery disease (CAD) and its complications.

Conclusions:

• Genetic variations in platelet receptors significantly impact antiplatelet therapy outcomes.
• Further research is needed to elucidate the clinical significance of common, often silent, genetic polymorphisms.
• Understanding these genetic factors is essential for optimizing antiplatelet treatment strategies and patient care.